Dec 14, 2022
Robert Hoffman President, CEO, and Chairman of the Board at Kintara Therapeutics, is developing a drug to treat glioblastoma, the most common and deadliest form of brain tumor. The only drug temozolomide, TMZ, was approved in 1999 and the overall survival rate is very limited. The Kintara drug VAL-083 crosses the...
Dec 14, 2022
Robert Hoffman President, CEO, and Chairman of the Board at Kintara Therapeutics, is developing a drug to treat glioblastoma, the most common and deadliest form of brain tumor. The only drug temozolomide, TMZ, was approved in 1999 and the overall survival rate is very limited. The Kintara drug VAL-083 crosses the...
Dec 13, 2022
Dr. Sean Bohen, President and CEO of Olema Oncology, is looking for a better endocrine option, alone or in the context of a CDK 4/6 inhibitor, to treat ER-positive, HER2-negative breast cancer. Their oral pill OP-1250 does not have chemotherapy-like side effects and could be better tolerated than chemotherapy to...
Dec 13, 2022
Dr. Sean Bohen, President and CEO of Olema Oncology, is looking for a better endocrine option, alone or in the context of a CDK 4/6 inhibitor, to treat ER-positive, HER2-negative breast cancer. Their oral pill OP-1250 does not have chemotherapy-like side effects and could be better tolerated than chemotherapy to...
Dec 5, 2022
Dr. Harvey Kaufman is the Senior Medical Director at Quest Diagnostics and Director of the Quest Diagnostics Health Trends Research, and he raises the alarm about the impact of delayed diagnostic testing for cancer due to the disruption of the COVID restrictions. While progress has been made on more...